Results 201 to 210 of about 113,942 (235)

Risk of fatal adverse events in cancer patients treated with sunitinib

Critical Reviews in Oncology/Hematology, 2019
Sunitinib, a tyrosine kinase inhibitor, is widely used in several malignancies. However, the association between sunitinib administration and fatal adverse events (FAEs) is not completely clear. Here, to calculate the overall incidence and relative risks (RRs) of FAE induced by sunitinib, PubMed and Embase were searched from inception to September 2017
Bin Zhao
exaly   +3 more sources

Potential risks and prevention, part 1: Fatal adverse drug events

American Journal of Health-System Pharmacy, 2001
Potential risk factors for and the preventability of fatal adverse drug events (ADEs) were studied. Case reports of ADEs published in Clin-Alert during 1976-95 were the source of information on fatal ADEs, Patient, drug, and event variables were identified, and the causality, predictability, and preventability of each case were assessed.
Kelly William N
exaly   +3 more sources

Can the Frequency and Risks of Fatal Adverse Drug Events Be Determined?

Pharmacotherapy, 2001
Death is the ultimate adverse drug event. Despite its importance, the frequency of fatal adverse drug events is unknown. Estimates in the United States are as high as 140,000/year, although this number is heavily disputed. Potential reasons and risks for fatal adverse drug events, as well as epidemiologic designs for studying this important public ...
exaly   +3 more sources

Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis

Journal of Chemotherapy, 2013
Cetuximab has been approved by FDA for the treatment of advanced/metastatic colorectal cancer. Whether cetuximab treatment is associated with an increase of severe adverse events in colorectal cancer (CRC) patients remains a question. The purpose is to assess the risk of severe adverse events of cetuximab treatment in advanced/metastatic CRC patients ...
Di, Zhang, Junjie, Ye, Tangpeng, Xu, Bin, Xiong   +3 more
exaly   +3 more sources

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis [PDF]

Frontiers in Medicine, 2021
Yanxia Zhang
exaly   +2 more sources

Adverse Event Fatalities Related to GI Endoscopy

Digestive Diseases and Sciences, 2021
Death after endoscopy is rare, under-reported, and has variable causes. This study aimed to evaluate the incidence and causes of fatal endoscopic adverse events (AEs) across two academic medical centers and to identify patient-, procedure-, and sedation-related risk factors.This is a retrospective cohort study of fatal adverse events causally related ...
Eric Swei, J. Christie Heller, Frank Scott, Augustin Attwell   +3 more
openaire   +2 more sources

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer [PDF]

Therapeutic Advances in Medical Oncology, 2020
Bin Zhao, Bin Zhao
exaly   +2 more sources

Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.

Journal of Clinical Oncology, 2019
2561 Background: Pembrolizumab, an immune checkpoint inhibitor (ICI) against programmed cell death-1(PD-1) protein has emerged as an effective treatment for many cancers. Although better tolerated than chemotherapy, it has unique immune related adverse event and little is known about its risk of fatal adverse events (FAE).
Amna F. Sher, Gol M. Golshani, Shenhong Wu   +2 more
openaire   +2 more sources